REFERENCES 1. Denis F, Garaud P, Bardet E, et al: Final results of the 94-01 GORTEC randomized trial comparing radiotherapy alone to concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 22:69-76, 2004[Abstract/Free Full Text] 2. Browman G, Cripps C, Hodson D, et al: Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol 12:2648-2653, 1994[Abstract] 3. Adelstein D, Saxton J, Lavertu P, et al: A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy aline in resectable stage III and IV squamous cell head and neck cancer: Preliminary results, chemoradiotherapy vs. radiotherapy. Head Neck 19:567-575, 1997[CrossRef][Medline] 4. Adelstein D, Li Y, Adams G, et al: An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92-98, 2003[Abstract/Free Full Text] 5. Brizel D, Albers M, Fisher S, et al: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338:1798-1804, 1998[Abstract/Free Full Text] 6. Dobrowsky W, Naude J, Widder J, et al: Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer. Int J Radiat Oncol Biol Phys 42:803-806, 1998[Medline] 7. Wendt T, Grabenbauer G, Rodel C, et al: Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study. J Clin Oncol 16:1318-1324, 1998[Abstract] 8. Staar S, Rudat V, Stuetzer H, et al: Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 50:1161-1171, 2001[Medline] 9. Jeremic B, Shibamoto Y, Milicic B, et al: Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial. J Clin Oncol 18:1458-1464, 2000[Abstract/Free Full Text] 10. Cox JD, Stetz J, Pajak T, et al: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341-1346, 1995[Medline] 11.NCI/CTC Web site. http://ctep.info.nih.gov 12. Denis F, Garaud P, Bardet E, et al: Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced stage oropharynx carcinoma: Comparison of the LENT/SOMA, RTOG/EORTC, and the NCI-CTC scoring sytems. Int J Radiat Oncol Biol Phys 55:93-98, 2003[Medline] 13. Rubin P, Constine S, Fajardo L, et al: Overview of late effects of normal tissues (LENT-SOMA) scoring system. Int J Radiat Oncol Biol Phys 31:1041-1042, 1995[Medline] 14. Calais G, Alfonsi M, Bardet E, et al: Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Nat Cancer Inst 91:2081-2086, 1999[Abstract/Free Full Text] 15. Trotti A: Toxicity in head and neck cancer: A review of trends and issues. Int J Radiat Oncol Biol Phys 47:1-12, 2000[Medline] 16. Trotti A, Byhardt R, Stetz J, et al: Common Toxicity Criteria, Version 2.0: An improved reference for the grading of acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 47:3-47, 2000 17. Trotti A: The evolution of toxicity criteria and reporting standards. Sem Rad Onc 12:1-3, 2002 (suppl 1) 18. Gwede C, Johnson D, Daniels S, et al: Assessment of toxicity in cooperative oncology trials: The long and short of it. J Oncol Manage 11:15-21, 2002 19. Bentzen S, Dorr W, Anscher M, et al: Normal tissue effects: Reporting and analysis. Semin Rad Oncol 13:189-202, 2003[CrossRef][Medline] 20. Bentzen S: Towards evidence based radiation oncology: Improving the design, analysis and reporting of clinical outcome studies in radiotherapy. Radiother Oncol 46:5-18, 1998[CrossRef][Medline] 21. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981[Medline] 22. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, WHO Offset publication No. 48, 1979 23. Dische S, Warburton M, Jones D, et al: The recording of morbidity related to radiotherapy. Radiat Oncol 16:103-108, 1989 24. Fu K, Pajak T, Trotti A, et al: A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 48:7-16, 2000[Medline] 25. CTC Manual CTEP Web site. http://ctep.info.nih.gov/CTC3/ctc.htm 26. US Food and Drug Administration Web site, pp 28. http://www.fda.gov/cder/guidance/issrvg08.pdf 27. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluaton and Research (CDER): Conducting a clinical safety review of a new product application and preparing a report on the review. www.fda.gov/OHRMS/Docket/98fr/03-5204.html 28. Trotti A, Colevas D, Setser A, et al: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 1:176-818, 2003 29. Moher D, Schultz K, Altman D: The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. Lancet 357:1191, 2001[CrossRef][Medline] 30. Adelstein D, Lavertu P, Saxton J, et al: Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer 88:876-883, 2000[CrossRef][Medline] 31. Browman G, Levine M, Hodson D, et al: The head and neck radiotherapy questionnaire: A morbidity/quality-of-life instrument for clinical trials of radiation therapy in locally advanced head and neck cancer. J Clin Oncol 11:863-872, 2003 32. Ioannidis JP, Lau J: Completeness of safety reporting in randomized trials: An evaluation of 7 medical areas. JAMA 285:437-443, 2001[Abstract/Free Full Text] 33. Ioannidis JP, Contopoulos-Ioannidis DG: Reporting of safety data from randomised trials. Lancet 352:1752-1753, 1998[Medline] Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.